[Hemodynamic effects of ST 155, 2-(2,6 dichlorophenylamino)-2 imidazoline hydrochloride, in hypertensive dogs].
D000005:Abdomen / Q000098:blood supply; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000098:blood supply; D002245:Carbon Dioxide / Q000096:biosynthesis; D002302:Cardiac Output / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects; D004285:Dogs; D005919:Glomerular Filtration Rate; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006977:Hypertension, Renal / Q000188:drug therapy*; D007093:Imidazoles / Q000494:pharmacology*; D007668:Kidney / Q000098:blood supply; D007866:Leg / Q000098:blood supply; D010101:Oxygen Consumption / Q000187:drug effects; D012039:Regional Blood Flow; D012119:Respiration / Q000187:drug effects; D014882:Water-Electrolyte Balance
D007093:Imidazoles; D002245:Carbon Dioxide
Effets hémodynamiques du ST 155, 2-(2,6 dichloro phenylamino)-2 imidazoline hydrochloride, chez le chien hypertendu.